Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

94.57
-0.1400-0.15%
Post-market: 94.660.0900+0.10%19:59 EDT
Volume:12.68M
Turnover:1.20B
Market Cap:238.89B
PE:14.03
High:94.88
Open:94.28
Low:93.45
Close:94.71
Loading ...

Merck Initiates Phase 3 Trial of Zilovertamab Vedotin Antibody-Drug Conjugate to Treat Lymphoma

MT Newswires Live
·
06 Feb

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
06 Feb

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Fortune
·
06 Feb

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

Benzinga
·
06 Feb

News Highlights: Top Company News of the Day - Wednesday at 1 PM ET

Dow Jones
·
06 Feb

Merck Is Maintained at Market Perform by BMO Capital

Dow Jones
·
05 Feb

Dow's 140-Point Fall Led By Losses For Shares Of UnitedHealth, Merck

Dow Jones
·
05 Feb

UBS Adjusts Price Target on Merck to $105 From $120, Maintains Buy Rating

MT Newswires Live
·
05 Feb

Merck Is Maintained at Buy by Citigroup

Dow Jones
·
05 Feb

BUZZ-Street View: Merck's Gardasil shipment pause hits investor confidence

Reuters
·
05 Feb

Merck & Company: Strong Q4 Performance and Strategic Diversification Justify Buy Rating Amid Competitive Challenges

TIPRANKS
·
05 Feb

Why Merck & Co. Inc. (MRK) Went Down on Tuesday

Insider Monkey
·
05 Feb

Merck call buyer realizes 48% same-day gains

TIPRANKS
·
05 Feb

Merck price target lowered to $96 from $105 at BMO Capital

TIPRANKS
·
05 Feb

Morgan Stanley Trims Price Target on Merck to $106 From $113, Keeps Equalweight Rating

MT Newswires Live
·
05 Feb

J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)

TIPRANKS
·
05 Feb